Quick Answer Psilocybin and other psychedelics show real, measurable promise for depression, particularly treatment-resistant cases. But the evidence in 2026 is more complicated, more honest, and more nuanced than headlines suggest. Whether this path is right for you...
Quick answer: A LSD For Anxiety randomized, placebo-controlled Phase 2b trial published in JAMA found that a single oral dose of MM120, an investigational LSD formulation developed by MindMed, produced significant reductions in generalized anxiety disorder symptoms...
The FDA rejected Lykos Therapeutics’ application for MDMA-assisted therapy for PTSD, citing three specific concerns: gaps in safety reporting, insufficient evidence that benefits lasted over time, and questions about who was enrolled in the trials. The MDMA...
Ketamine therapy preparation is not a formality you complete before the real thing begins. It is a functional part of what makes the treatment work. What you do before your session, how you move through it, and how you integrate what surfaces afterward determines...
Psychedelic guide matching is one of the most important decisions a seeker can make, and at JourneyOM, it is never left to an algorithm. This post explains how JourneyOM’s concierge model works, why the match matters as much as the medicine, and what to expect...
RFK Jr. psychedelic therapy support has brought real political attention to substances like psilocybin, MDMA, and ibogaine. For seekers already exploring this space, the shift matters. It does not, however, change what responsible engagement looks like at the...
